Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 09, 2024 08:05 ET | Source: Ardelyx, Inc.

Ardelyx Announces Publication of a Review Article Exploring the Patient Burden and Therapeutic Landscape of IBS-C in the U.S. in Clinical and Experimental Gastroenterology

WALTHAM, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...
September 05, 2024 08:00 ET | Source: Ardelyx, Inc.

Ardelyx to Participate at the 2024 Cantor Global Healthcare Conference

WALTHAM, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...
August 08, 2024 08:00 ET | Source: Ardelyx, Inc.

Ardelyx Appoints Experienced Biopharma Executive, Eric Foster, as Chief Commercial Officer

WALTHAM, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...
August 01, 2024 16:01 ET | Source: Ardelyx, Inc.

Ardelyx Reports Second Quarter 2024 Financial Results and Provides Business Update

IBSRELA generates $35.4 million in net product sales revenue XPHOZAH generates $37.1 million in net product sales revenue Company ends Q2 with approximately $186 million in cash and investments ...
July 31, 2024 08:02 ET | Source: Ardelyx, Inc.

Ardelyx Announces Publication of Two Plain Language Summaries from XPHOZAH® (tenapanor) Clinical Trials in Current Medical Research and Opinion

WALTHAM, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...
July 18, 2024 08:00 ET | Source: Ardelyx, Inc.

Ardelyx to Report Second Quarter 2024 Financial Results on August 1, 2024

WALTHAM, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...
July 17, 2024 17:10 ET | Source: Ardelyx, Inc.

Ardelyx, AAKP and NMQF File Lawsuit to Protect Dialysis Patient Choice and Timely Access to Clinically Meaningful Medicines

Lawsuit challenges CMS’s statutory overreach in its determination to include oral-only phosphate-lowering therapies in the End-Stage Renal Disease Prospective Payment System Inclusion of oral-only...
July 02, 2024 07:00 ET | Source: Ardelyx, Inc.

To Preserve Patient Access to XPHOZAH®, Ardelyx Chooses Not to File for TDAPA

Ardelyx continues support for bipartisan legislation that would extend the exclusion of oral-only medications from entering the CMS Prospective Payment System Conference call scheduled for 8:00 AM...
June 28, 2024 08:17 ET | Source: Ardelyx, Inc.

Ardelyx Presents Additional Data Detailing Educational Needs Related to IBS-C Management Across Healthcare Disciplines

WALTHAM, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...
May 30, 2024 16:02 ET | Source: Ardelyx, Inc.

Ardelyx, Inc. Reports Employment Inducement Grants

WALTHAM, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...